For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval that, according to one of the world’s leading leukemia experts, is showing “significant ...

Michael J. Mauro, MD, leader of the Myeloproliferative Neoplasms Program, Leukemia Service, at Memorial Sloan Kettering Cancer Center, discusses the current understanding of TKI discontinuation ...

July 2, 2012 — The outlook has never been better for patients with chronic myeloid leukemia (CML). Clinicians have an increasingly wide choice of drugs, between imatinib (Gleevec), dasatinib ...

Ask the Expert: More about Treatment-free CML after TKI —In the second part of this interview, Michael J. Mauro, MD, discusses the possible risks of stopping TKI therapy and what we still need ...